Updated Jan 03, 2021 | 13:22 IST
The drug regulator has given a conditional nod to SII's Covishield and Bharat Biotech's Covaxin. Permission was also granted for Cadila Healthcare's Phase 3 trials.
Representational Image 
Drug Regulator accepts SEC's recommendations, gives conditional nod for Covishield, Covaxin
PM hails the nod for SII & Bharat Biotech vaccines as a decisive turning point in fight against COVID
2021 promises to the year of vaccination in India and elsewhere
Looking back, we didn’t know what was coming when 2020 descended upon us. While the whispers of a virus spreading in Wuhan were reported in earnest by the wires, they did not cause a storm, not then.